TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed follicular non-Hodgkin's lymphoma~  * Diagnosed within the past 3 months~ * Grade 1, 2, or 3a disease~ * Stage II-IV disease~ * No evidence of histological transformation~* Bidimensionally measurable disease by clinical examination or radiography~* Asymptomatic disease without B symptoms or severe pruritus~* Low tumor burden, defined by all of the following criteria:~  * Lactic dehydrogenase normal~ * Largest nodal or extranodal mass \< 7 cm~ * No more than 3 nodal sites with a diameter \> 3 cm~ * No clinically detectable significant serous effusion by chest x-ray~    * Clinically non-evident small effusion on CT scan is not considered significant~ * Spleen enlargement ≤ 16 cm by CT scan~* Circulating tumor cells \< 5,000/mm\^3~* No organ compression (i.e., ureteric obstruction)~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-1~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count \> 1,500/mm\^3~* Platelet count \> 100,000/mm\^3~* Hemoglobin \> 10 g/dL~Hepatic~* AST and ALT normal~* Alkaline phosphatase normal~* Bilirubin normal~Renal~* Creatinine \< 2 times upper limit of normal (unless due to lymphoma)~Other~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 12 months after completion of rituximab~* No known HIV positivity~* No other malignancy within the past 2 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~* No critical organ failure~* No other immediate life-threatening disease~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Not specified~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified~Other~* No prior therapy for lymphoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Watch and Wait (Type: ACTIVE_COMPARATOR): Watch and Wait - no treatment
- Arm C Rituximab 4 and Rixuximab Maintenance (Type: EXPERIMENTAL): 4 infusions - 375mg/m2 every 2 months. A single dose of rituximab (375mg/m2 will then be given at 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92 and 100 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Butylphthalide on Dynamic Cerebral Autoregulation in Patients With Acute Ischemic Stroke.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ranging from 18 to 80, both genders;~* Within 48 hours symptoms onset;~* According to TOAST classification, diagnosed to be large-artery atherosclerosis ischemic stroke, without history of stroke in the past three months;~* 5≤National Institutes of Health Stroke Scale (NIHSS) ≤25;~* Unilateral internal carotid artery (ICA) or M1 segment of middle cerebral artery (MCA) stenosis (rate of stenosis ranging from 50-99%);~* Sufficient bilateral temporal bone windows for insonation of the middle cerebral artery;~* Glasgow Coma Scale (GCS) ≥ 8;~* Willing to participate and sign the informed consent.~Exclusion Criteria:~* Patients who have received or plan to undergo intravascular interventional treatment/thrombolytic therapy;~* Coma or agitation, and can't cooperate to complete dCA;~* Has been given butylphthalide injection or capsules;~* Arrhythmia, anemia and hyperthyroidism which may influence the stability of cerebral blood flow diagnosed by two physicians by electrocardiogram and laboratory tests;~* Other intracranial diseases, including cerebral hemorrhage (primary or secondary), intracranial neoplasm, aneurysm, arteriovenous malformation, etc;~* Alanine transaminase (ALT) or glutamic-oxalacetic transaminase (AST) continued to rise more than 3 times the upper limit of normal , creatinine clearance rate\<30ml/min;~* Pre-stroke Modified Rankin Scale (mRS) score ≥ 2;~* Malignant neoplasm and expected lifetime \< 2 years;~* Pregnant and lactating women;~* Participating in other trials or has been participated in other trials in recent 3 months;~* Dementia and mental illness.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- butylphthalide(NBP) (Type: EXPERIMENTAL): Based on the standard medical care, 25mg of NBP injection, and 100ml of 0.9% saline; NBP capsule
- placebo (Type: PLACEBO_COMPARATOR): Based on the standard medical care, 100ml of 0.9% saline as the placebo; starch capsule as the placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cannabidiol Use to Reduce Cravings in Individuals With Opioid Use Disorder on Buprenorphine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Diagnostic and Statistical Manual of Mental Disorders (DSM-5) opioid use disorder, severe~* Currently in treatment with methadone or buprenorphine~Exclusion Criteria:~* Requiring level of care higher than outpatient treatment for alcohol, sedative/hypnotics, or stimulants~* Any current mood episode requiring level of care higher than outpatient treatment~* History of psychotic disorder or bipolar disorder~* Currently pregnant~* Hepatic liver enzymes greater than 3x upper normal limit~* Hypersensitivity to cannabinoids or sesame oil (cannabidiol solution comes in sesame oil emulsion)~* Currently taking any medications with known significant pharmacokinetic interactions with CBD

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Cannabidiol (Type: EXPERIMENTAL): As this is a single-arm, open-label study, all subjects will receive the interventional arm, specifically 600mg of oral cannabidiol once daily for 3 consecutive days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Male or female subjects (aged 18 or older)~2. Subjects diagnosed with open-angle glaucoma or ocular hypertension, and determined by the treating physician to require additional intraocular pressure (IOP)-lowering treatment with netarsudil 0.02%.~3. Willingness to follow protocol requirements, including signed informed consent, routine follow-up schedule, completing questionnaires and completing laboratory tests~Key Exclusion Criteria:~1. Have any active ocular disease other than glaucoma or ocular hypertension that would interfere with study interpretation~2. Women of childbearing potential who are pregnant, nursing, or planning a pregnancy and not using a medically acceptable form of birth control. Male subjects with a female partner of childbearing potential must have had a prior vasectomy or agree to use an effective method of birth control during the treatment period and for 3 months after the subject has completed the study.~3. Known sensitivity or allergy to the study medication or components~4. Any systemic disease or clinical evidence of any condition which would make the subject, in the opinion of the investigator, unsuitable for the study or could potentially confound the study results~5. Concurrent participation or prior participation in any investigational drug or device study within the last 30 days prior to the Baseline Visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Netarsudil Ophthalmic Solution 0.02% (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older.~* Diagnosis of low or Int-1 risk MDS~* Low platelet count, and/or low hemoglobin, and/or RBC transfusion-dependent and/or platelet transfusion-dependent~* ECOG Performance status 0-2~* Standard safety inclusion for serum creatinine, AST, ALT, bilirubin.~* Serum bicarbonate greater than or equal to 20 mEq/L.~* Use of acceptable birth control.~* Signed, written informed consent.~Exclusion Criteria:~* Diagnosis of acute PML.~* Previous or concurrent malignancy.~* Prior treatment with azacitidine or other demethylating agents.~* Treatment with any anticancer therapy or investigational drugs within 21 days.~* Hypersensitivity to azacitidine or mannitol.~* Presence of GI disease.~* Active, uncontrolled infection.~* Known Human Immunodeficiency Virus (HIV) or Hepatitis C, or known active viral Hepatitis B.~* Breastfeeding or Pregnant females;~* Presence of serious illness, medical condition, or other medical history which would be likely to interfere with a subject's participation in the study or with the interpretation of the results.~* Current congestive heart failure (NY Heart Association Class III-IV), unstable angina or angina requiring surgical or medical intervention within 6 months, myocardial infarct within 6 months, or uncontrolled cardiac arrhythmia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subcutaneous (SC) Azacitidine and Oral Azacitidine (Type: EXPERIMENTAL): Cycle 1 subjects receive SC Azacitidine for first 7 days of 28 day cycle. For Cycle 2 and beyond subjects receive Oral Azacitidine (experimental) for first 7 days of 28 day cycle.
- Oral Azacitidine (Type: EXPERIMENTAL): Subjects receive Oral Azacitidine (experimental) QD or BID for the first 14 or 21 days of 28 day cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Netarsudil Use After Descemtorhexis Without Endothelial Keratoplasty

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Fuchs corneal dystrophy~Exclusion Criteria:~* Women of childbearing potential~* Other corneal eye diseases~* Non-compliance with netarsudil~* Intolerance of netarsudil

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Netarsudil use (Type: EXPERIMENTAL): Patients will receive Netarsudil eye drops to use 1 drop nightly in the operative eye after DWEK surgery until corneal clearance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CHAMP: Study of NVK-002 in Children With Myopia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Children aged 3 to ≤ 17.0 years.~2. Myopia SER of at least -0.50 D and no worse than -6.00 D myopia in each eye as measured by cycloplegic autorefraction.~Exclusion Criteria:~1. If present, astigmatism more than -1.50 D in either eye.~2. Current or history of amblyopia or strabismus.~3. History of any disease or syndrome that predisposes the subject to severe myopia (e.g., Marfan syndrome, Stickler syndrome, retinopathy of prematurity).~4. History in either eye of abnormal ocular refractive anatomy (e.g., keratoconus, lenticonus, spherophakia).~5. Serious systemic illness that, in the Investigator's opinion, would render the subject ineligible.~6. Chronic use (more than 3 days per week) of any topical ophthalmic medications (prescribed or over the-counter) other than the assigned study medication.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- NVK-002 Concentration 1 (Type: EXPERIMENTAL): Stage 1: Subjects will be randomized to NVK-002 Concentration 1~Stage 2: Subjects will be re-randomized to one of the three treatment arms.
- NVK-002 Concentration 2 (Type: EXPERIMENTAL): Stage 1: Subjects will be randomized to NVK-002 Concentration 2~Stage 2: Subjects will be re-randomized to one of the three treatment arms.
- Vehicle (Placebo) (Type: PLACEBO_COMPARATOR): Stage 1: Subjects will be randomized to Vehicle (Placebo)~Stage 2: Subjects will be re-randomized to one of the two experimental NVK-002 treatment arms

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Activase (Ateplase) vs Placebo in Complicated Pleural Effusions (CPE)/Empyemas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with complicated pleural effusions~* Ability to provide written informed consent and comply with study assessments for the full duration of the study.~* Age \> 18 years~Exclusion Criteria~* Current use of oral anticoagulants (e.g., warfarin sodium) with an International Normalized Ratio (INR) \>5- Activated partial thromboplastin time (aPPT) \> 80, Platelet count \< 100,000/mm3;~* Severe uncontrolled hypertension~* Recognized hypersensitivity to Activase; or any component of its formulation; Traumatic pleural effusion~* Pregnancy (positive pregnancy test)~* In another study for this condition~* Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated~* Participation in another simultaneous medical investigation~* Recent stroke~* Intracranial hemorrhage~* arteriovenous malformation or aneurysm~* Intracranial neoplasm~* Acute myocardial infarction~* Acute pulmonary embolus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alteplase, Placebo- intapleural instillation (Type: ACTIVE_COMPARATOR): Either 25 mg of Alteplase or Placebo instilled daily. Response to therapy after three days. cross over to the other drug if no response was noted.
- Placebo, Alteplase -2nd arm (Type: ACTIVE_COMPARATOR): If the first arm fails then the 2nd arm ( cross over to either Placebo or Alteplase not used in the first arm) instilled intrapleurally daily for three days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.~Inclusion Criteria:~* Severe hemophilia (defined as \< 1% factor activity level)~* Infection with the hepatitis C virus (HCV) with underlying hemophilia~* Males 18 years of age and above~* Have not been previously treated with an interferon~Exclusion Criteria:~* Not infected with the hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~* Chronic liver disease caused by any disease other than chronic HCV infection~* Presence of Bethesda inhibitor~* Current evidence of or history of portal hypertension

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A: Genotype-2,-3 (Lambda/RBV/DCV) (Type: EXPERIMENTAL): Lambda 180 μg solution for subcutaneous (SC) injection, once weekly for 12 weeks~Ribavirin (RBV) 200 mg tablet by mouth (oral), twice daily for 12 weeks~Daclatasvir (DCV) 60mg tablet by mouth (oral), once daily for 12 weeks
- Cohort B: Genotype-1b,-4 (Lambda/RBV/DCV) (Type: EXPERIMENTAL): Lambda 180 μg solution for subcutaneous (SC) injection, once weekly for 24 weeks~Ribavirin (RBV) 200 mg tablet by mouth (oral), twice daily for 24 weeks~Daclatasvir (DCV) 60mg tablet by mouth (oral), once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RIGHT: Rhythm ID Going Head-to-Head Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who meet current indications for an ICD~* Patients who sign and date a Patient Informed Consent form prior to the implant visit~* Patients who remain in the clinical care of the enrolling physician in approved centers~* Patients who are able to tolerate ICD programming as specifically prescribed in the study protocol~Exclusion Criteria:~* Patients who are in third degree heart block~* Patients whose life expectancy is less than 12 months~* Patients who have other cardiac surgeries or procedures planned but not yet performed during the duration of the study~* Patients who are currently enrolled in another investigational study or registry that would directly impact the treatment or outcome of the current study~* Patients who are younger than 18 years of age~* Patients who are mentally incompetent and cannot sign a Patient Informed Consent form or comply with the study~* Patients who are pregnant or plan to become pregnant during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Implantable Cardioverter Defibrillator - Boston Scientific (Type: ACTIVE_COMPARATOR): VITALITY 2 ICD
- Implantable Cardioverter Defibrillator - Medtronic (Type: ACTIVE_COMPARATOR): Selected Medtronic family ICD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Multimodal Peri- and Intraarticular Drug Injections in Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* patients at least 18 years of age~* scheduled for elective total knee arthroplasty~* ASA I-III~* signed written informed consent~Exclusion Criteria:~* age \< 18~* ASA \> III~* moderate or severe cardiac disease, bronchial asthma~* allergy against ropivacaine, ketorolac or morphine~* analgetic abuse~* pregnancy or nursing women~* severe psychiatric disease~* moderate to severe dementia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LIA IV (Type: EXPERIMENTAL): Local infiltration analgesia with ropivacaine and adrenaline and intravenous ketorolac and morphine
- LIA IA (Type: EXPERIMENTAL): Local infiltration analgesia with ropivacaine, adrenaline and ketorolac and morphine
- EDA (Type: ACTIVE_COMPARATOR): standard continuous epidural analgesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Efficacy Assessment of Geltim LP® 1 mg/g in Ocular Hypertensive or Glaucomatous Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent.~* Association of the 4 following criteria:~  1. - Bilateral primary open angle glaucoma or bilateral ocular hypertension already treated and controlled by mono-therapy of Xalatan® (1drop per day),~ 2. - With local intolerance signs.~Exclusion Criteria:~* Presence of severe objective ocular sign.~* Any ocular hypertension other than primary ocular hypertension or primary chronic open angle glaucoma (such as congenital, angle closure glaucoma, secondary glaucoma).~* Absolute defect in the ten degrees central point of the visual field.~* Best far corrected visual acuity ≤ 1/10.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Geltim LP® (Type: EXPERIMENTAL): Geltim LP® 1 mg/g (0.1 % timolol maleate, without preservative) packaged in single-dose containers (unidoses); one drop in the conjunctival sac of each eye in the morning (84 days).
- Xalatan® (Type: ACTIVE_COMPARATOR): Xalatan® (Latanaprost) aqueous eye drop (one drop in the conjunctival sac of each eye in the evening during 84 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Uncomplicated Malaria in Benin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 6-119 months old~* fever or history of fever of less than 24 hours~* p falciparum parasitemia \> 1000 trophozoïtes/µL~* informed consent signed~Exclusion Criteria:~* \< 5 kg~* danger or severity signs of malaria~* known underlying chronic disease~* Hb \< 5g/dL~* adequate malaria treatment taken within 3 days before visit

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 119 Months
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): sulfadoxine-pyrimethamine
- 2 (Type: ACTIVE_COMPARATOR): artemether-lumefantrine
- 3 (Type: ACTIVE_COMPARATOR): amodiaquine-artesunate coformulation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete